Index of Articles From 1995 TAGlines

About TAGlines

December, 1995
- CMV's Real World
  When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary - A question of patient management
- Giving Away the Farm
  How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals - "Grave disservice to the public health"
- Random Gleanings
  Tracking down the elusive CD8 cell factor, FDA panel recommends approval for ganciclovir implant, FDA approval for saquinavir; Lottery for ritonavir
- Subsctiption Information
November, 1995
- Antiretroviral Horizon
  35th Interscience Conference Unveils Results from Several Important Clinical Studies - Protease and paradox
- I'll Take Los Angeles
  AIDS Treatment Activists from Across the Land Gather to Share Expertise and Ideas - "A conversation long overdue"
- Random Gleanings
  FDA Antiviral Drugs Advisory Committee, Ambushed in the FDCs, Expanding T cells: Koenig weighs in on Good CTLs/Bad CTLs debate
October, 1995
- "Kiss My Access"
  Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access - "Badgering, hijacking activists"
- Reversal of Fortune
  Despite Pressure to Crown Combo King, 175 Investigators Soft-Pedal Combination Nucleoside Study's Startling Findings - The didanosine surprise
- Washington Woes
  Senate Appropriations Committee, the OAR's blue-ribbon review of the NIH AIDS program, TAG's Gregg Gonsalves, AmFAR Public Policy Director Jane Silver
- Conclusions for ACTG 175
September, 1995
- Batten Down the Hatches
  House Republican Plan Calls for AIDS Research Dollars to Be Mixed Into Pot For All to Avail Themselves Of - The OAR as paper tiger
- Combo Jumbo
  Controversial Nucleoside Study Awakens To A World Strangely Disaffected By Its Prepackaged Proclamation - Beware the Composite endpoint
- Now Available From The Tag Bookshelf
August, 1995
- Science South of the Border
  Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future - Wrangling over control arm
- Diversity Threshold
  New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome - Sloppy RT, Bane of All
April, 1995
- Integrase: The Next Viral Target
  With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit--Or Will It Be 'Three Up, Three Down?'
- The Doxil NDA
  FDA's Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval--But Not Without A Fight
March, 1995
- Random Gleanings
  FDA Just Says "No" To Salk Immunogen, Heralding the Naked Emperor (Part II), OAR's Dr. Paul Speaks, Varmus Selects New Director for Office of Alternative Medicine
- Dr. Emini's Gamble
  Merck's Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash
- Souped-Up Abs from LTNPs
  Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for "Bad" Cytokines; Parke-Davis Targets Cellular Factors
February, 1995
- The CTL As Both Villain and Victor
  Fascinating Work on HIV and T-Cell Kinetics Challenges Longtime Dismissal of Ravaged Immune System's Regenerative Potential
- Re-Inventing Government
  New ACTG Structure Squeezes Eleven Committees Into Three--But Will Anything Really Be Any Different?
- Hope for Sale
  Like the Wings of Icarus, Treatment Hype Sweeps Its prey Upward to the Heavens, Then Plucks Them Down Into icey Waters
January, 1995
- When Viral Load Is Crowned King
  With Good Intenntions, Over-Zealous Researchers May Be Setting the Stage For Yet Another Colossal Failure
- Tyranny of the Minority
  What the New Republican Congress Will Mean for AIDS Prevention, Treatment and Research

Back to the Treatment Action Group index page